Post-test – Contemporary Considerations in Multiple Sclerosis Treatment

Home
CE Information
- Pre-test
- Content
- Post-test
- Evaluation
- Conclusion

Post-test

Please choose the best answer for all the questions below, then click the button at the bottom to proceed.

Items with * require a response.
Please enter your email address*
1. In a recent international study of more than 1500 patients with relapsing-remitting MS, published in 2019 by Brown et al, early initiation of disease-modifying therapy (DMT) significantly reduced the risk of conversion to secondary progressive MS, compared with later initiation. How was “early” initiation defined?*
- Within 1 year of disease onset
- Within 5 years of disease onset
- Before reaching Expanded Disability Status Scale score of 3.0
- Before reaching Expanded Disability Status Scale score of 4.0
2. The same study by Brown et al found that initiation of treatment with a high-efficacy therapy (ie, alemtuzumab, fingolimod, or natalizumab), compared with an older injectable therapy (ie, interferon beta or glatiramer acetate), was associated with which of the following?*
- 34% reduction in risk of 3-month confirmed disability progression
- 74% reduction in risk of 3-month confirmed disability progression
- 34% reduction in risk of conversion to secondary progressive MS
- 74% reduction in risk of conversion to secondary progressive MS
3. Consistent with its mechanism of action, which of the following DMTs often causes an increase in the total number of peripheral lymphocytes?*
- Natalizumab
- Ofatumumab
- Ozanimod
- Teriflunomide
4. Which of the following statements related to COVID-19 vaccination in people with MS receiving anti-CD20 B-cell depleting therapy is correct?*
- There is a risk of infection from the vaccine
- There is a risk of reduced antibody response to the vaccine
- Primary and booster vaccines should not be given within 3 months of last DMT dose
- Use of prophylactics after suboptimal vaccine response is not recommended